By: Patrick Sullivan, Chair of the BioCanRx Cancer Stakeholder Alliance Working Group I have been asked to give an update on the Cancer Stakeholder Alliance (CSA) created by BioCanRx. BioCanRx created the CSA because they (rightly) recognized that patients have an important and powerful voice that is critically important to advancing cancer immunotherapies. 2017… Read more »
Tag: Cancer Stakeholder Alliance
Learning Institute Community Dissemination Report 2017
The participants of the 2017 BioCanRx-Cancer Stakeholder Alliance Learning Institute wish to share their Community Dissemination Report with the oncology patient and researcher community, BioCanRx, the Cancer Stakeholder Alliance, and the general public. In this report, you will find the key research take-away messages and the Learning Institute’s group reflections on the topics listed below… Read more »
Lasting Impacts of The Learning Institute
By: Kathy Brodeur-Robb, Executive Director, C17 Council With input from Gabrielle Siegers, Research Associate, Department of Experimental Oncology, University of Alberta, and Brittany Umer, Graduate Student, Dep’t of Medical Microbiology & Immunology, University of Alberta. BioCanRx invited participants from the Cancer Stakeholder Alliance to help develop the BioCanRx Learning Institute. “Sure!” I said; it… Read more »
The Learning Institute Pilot – Testimonials From Participants
The BioCanRx-Cancer Stakeholder Alliance Learning Institute debuted at this year’s Summit for Cancer Immunotherapy. The pilot model was developed and organized by members of the Cancer Stakeholder Alliance Working Group and our HQP community. It brought together patient/public leaders and academic scholars in an interactive and collaborative knowledge exchange program. We asked two of the participants, a… Read more »
